ABSTRACT - 597270 The disclosure relates to the use of a pyrimidine nucleotide precursor selected from the group consisting of uridine, an acyl derivative of uridine, cytidine, and an acyl derivative of cytidine, preferably 2',3',5'-tri-O-acetyluridine, for manufacture of a medicament for reducing side effects of a cytotoxic cancer chemotherapy agent that is not a pyrimidine nucleoside analog, wherein the side effects of cytotoxic cancer chemotherapy are selected from the group consisting of peripheral neuropathy, chemotherapy-induced menopause, chemotherapy-associated fatigue, and depressed appetite.
